NICE backs Novartis’ Aimovig for prevention of episodic and chronic migraine

pharmafile | December 11, 2020 | News story | Medical Communications, Sales and Marketing |  Aimovig, NICE, Novartis, migraine 

NICE has announced its decision to recommended Novartis’ Aimovig (erenumab) for the prevention of migraine, including both episodic and chronic migraine, on routine NHS use in England and Wales.

An appeal was launched to challenge an earlier decision by NICE to reject the therapy, urging the watchdog to consider the cost-effectiveness of the drug in treating chronic migraine in patients who did not respond adequately to botulinum toxin or when it is contra-indicated.

NICE revisited the case, including new data supplied by Novartis, and believed the evidence base was now sufficient to recommend the use of the drug in adult patients who experience at least four migraine days each month and who have not seen their condition improve despite receiving at least three previous preventive treatments.

While Aimovig costs around ÂŁ5,000 per patient per year, the NHS has agreed with Novartis to access the drug at a confidential discounted price.  

Advertisement

NICE is anticipated to publish final guidance on its decision in January next year.

Matt Fellows

Related Content

Digital mental health technologies – a valuable tool in supporting people with depression and anxiety

The potential benefits of digital mental health technology for managing depression, anxiety and stress, together …

Teva’s Ajovy significantly reduces migraine in children and adolescents

Teva’s Ajovy (fremanezumab) has demonstrated significant reduction in monthly migraine and headache days in children …

Teva announces positive results from trial of AJOVY for migraine

Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its …

The Gateway to Local Adoption Series

Latest content